CD274 and renal cell adenocarcinoma: A second turning point in the treatment of RCC was the application of immunotherapy with checkpoint (PD-L1) inhibitors, which improved OS in patients previously treated with angiogenesis inhibitors and demonstrated immune-mediated mechanisms of tumor control (Motzer et al. 2015a, b).